Table 1.

Data Inputs in Economic Model

	Mean	Standard error	Implicit sample size	Distribution	Source
Baseline treatment probabilities
Revascularization	0.80	0.06	50	Beta	SCRR
PCI conditional on revascularization	0.85	0.05	50	Beta	SCRR
DEFER conditional on no revascularization	0.40	0.09	30	Beta	SCRR
Baseline 1-yr MACE probability	0.20	0.06	50	Beta	SCRR
Probability death conditional on MACE in year 1	0.06	–	–	Deterministic	SCRR
Life expectancy conditional on death in year 1 (yrs)	0.36	–	–	Deterministic	SCRR
Unit Costs (GBP)
Index PCI	3410	208	50	Normal	SCRR & NHS reference costs
Index CABG	10180	520	50	Normal	SCRR & NHS reference costs
DEFER	7622	48	50	Normal	NHS reference costs & expert opinion (CB)
MACE	4400	622	50	Normal	SCRR & NHS reference costs
Pressure Wire (PW)	400	–	–	Deterministic	St Jude's Medical Centre
Adenosine (drug used with PW)	30	–	–	Deterministic	BNF 62
Medical Management year 1a	510	–	–	Deterministic	BNF 62
Medical Management years 2+b	153	–	–	Deterministic	BNF 62
Long term annual cost	390	55	50	Normal	SCRR & NHS reference costs
No. of pressure wires	1.3	0.60	100	Normal	FAME
Additional life expectancies (discounted)
No MACE	8.8	2.20	10	Normal	NICE guidelines CG94
MACE	5.3	1.30	10	Normal	NICE guidelines CG94
Quality-adjusted life-years
Baseline	0.80	0.09	19	Beta	Palmer et al. (2005)(24)
Utility decrement with MACE (year 1)	0.05	0.04	20	Beta	Palmer et al. (2005)
Treatment distribution – odds ratios
Revascularisation	0.88	0.33	48	Lognormal	Retrospective data
PCI conditional on revascularisation	0.96	0.43	41	Lognormal	Retrospective data
DEFER conditional on revascularisation	0.02	0.03	5	Lognormal	Retrospective data
MACE 1-year odds ratio	0.67	0.34	16	Lognormal	FAME
Relative price PCI in PW	1.00	0.2	10	Lognormal	FAME

^aAspirin (75mg), Bisoprolol (5mg), Ramipril (10mg), Simvastatin (40mg), Nitrate (20mg), Clopidogrel (90mg). All per day; ^bAs for year 1 but without Clopidogrel.